Porter D E, Lonie L, Fraser M, Dobson-Stone C, Porter J R, Monaco A P, Simpson A H R W
Edinburgh University Department of Orthopaedic Surgery, New Royal Infirmary of Edinburgh, Little France, Edinburgh EH16 4SU, UK.
J Bone Joint Surg Br. 2004 Sep;86(7):1041-6. doi: 10.1302/0301-620x.86b7.14815.
We performed a prospective genotype-phenotype study using molecular screening and clinical assessment to compare the severity of disease and the risk of sarcoma in 172 individuals (78 families) with hereditary multiple exostoses. We calculated the severity of disease including stature, number of exostoses, number of surgical procedures that were necessary, deformity and functional parameters and used molecular techniques to identify the genetic mutations in affected individuals. Each arm of the genotype-phenotype study was blind to the outcome of the other. Mutations EXT1 and EXT2 were almost equally common, and were identified in 83% of individuals. Non-parametric statistical tests were used. There was a wide variation in the severity of disease. Children under ten years of age had fewer exostoses, consistent with the known age-related penetrance of this condition. The severity of the disease did not differ significantly with gender and was very variable within any given family. The sites of mutation affected the severity of disease with patients with EXT1 mutations having a significantly worse condition than those with EXT2 mutations in three of five parameters of severity (stature, deformity and functional parameters). A single sarcoma developed in an EXT2 mutation carrier, compared with seven in EXT1 mutation carriers. There was no evidence that sarcomas arose more commonly in families in whom the disease was more severe. The sarcoma risk in EXT1 carriers is similar to the risk of breast cancer in an older population subjected to breast-screening, suggesting that a role for regular screening in patients with hereditary multiple exostoses is justifiable.
我们进行了一项前瞻性基因型-表型研究,采用分子筛查和临床评估,以比较172例(78个家系)遗传性多发性骨软骨瘤患者的疾病严重程度和肉瘤风险。我们计算了疾病严重程度,包括身高、骨软骨瘤数量、必要的手术数量、畸形和功能参数,并使用分子技术鉴定受影响个体的基因突变。基因型-表型研究的每个环节对另一个环节的结果均不知情。EXT1和EXT2突变几乎同样常见,在83%的个体中被鉴定出来。使用了非参数统计检验。疾病严重程度存在很大差异。10岁以下儿童的骨软骨瘤较少,这与该疾病已知的年龄相关外显率一致。疾病严重程度在性别上无显著差异,且在任何给定家族中差异很大。突变位点影响疾病严重程度,在五个严重程度参数(身高、畸形和功能参数)中的三个参数上,携带EXT1突变的患者病情明显比携带EXT2突变的患者更严重。一名EXT2突变携带者发生了1例肉瘤,而EXT1突变携带者中有7例。没有证据表明肉瘤在疾病更严重的家族中更常见。EXT1携带者的肉瘤风险与接受乳房筛查的老年人群中的乳腺癌风险相似,这表明对遗传性多发性骨软骨瘤患者进行定期筛查是合理的。